Psoriatic Arthritis
From the Journals
Evidence builds for effects of obesity, low physical activity on development of psoriatic arthritis
The study “adds to the growing evidence that the risk of PsA is modifiable and highlights the importance of preventive work against obesity as...
Conference Coverage
Repeat LTBI testing best in patients taking biologics with new risk factors
ATLANTA – Just 1.2% of patients taking biologics with negative tuberculosis test results converted to positive results in annual tuberculosis...
News from the FDA/CDC
FDA approves infliximab-axxq for numerous indications
This is the fourth biosimilar for this tumor necrosis factor inhibitor to receive FDA approval.
Conference Coverage
Certolizumab safety profile varies widely across indications
MADRID – Systemic corticosteroid use and BMI impact risk of serious adverse events with certolizumab.
Commentary
More studies like VERVE needed to test live vaccines in special populations
“This study was narrow in nature and we certainly need more information on the safety of Zostavax with patients on biologics with other mechanisms...
Conference Coverage
SPIRIT-H2H results confirm superiority of ixekizumab over adalimumab for PsA
ATLANTA – Biologic-naive patients with PsA responded better to ixekizumab than to adalimumab for skin and joint symptoms, and at least as well...
From the Journals
Ixekizumab effective over long term for psoriasis
The monoclonal antibody ixekizumab has shown efficacy in moderate to severe psoriasis over a 4-year follow-up.
News from the FDA/CDC
FDA announces approval of fifth adalimumab biosimilar, Abrilada
Pfizer said that current plans are to launch the drug in the United States in 2023.
Conference Coverage
Expert shares tips for TNF-alpha inhibitor use in special populations
LAS VEGAS – Optimizing anti-TNF-alpha treatment starts with recognizing there is a loss of response over time, Dr. Kerdel said.
Conference Coverage
Narrowband UVB phototherapy an effective treatment for psoriasis
LAS VEGAS – Home-based UVB phototherapy is gaining in popularity and is comparable with in-office UVB in terms of accuracy and efficacy.
Conference Coverage
Guselkumab improves psoriatic arthritis regardless of prior TNFi use
ATLANTA – Guselkumab, an anti-IL-23p19 monoclonal antibody, showed efficacy versus placebo for active PsA in both biologic-naive and TNFi-treated...